Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sohail Ikram

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Circulation. Cardiovascular Interventions|December 17, 2017
Thirty-Day Readmission Rate and Costs After Percutaneous Coronary Intervention in the United States: A National Readmission Database AnalysisAvnish Tripathi, J Dawn Abbott, Gregg C Fonarow, et al.
Lancet (London, England)|November 18, 2011
Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trialRoberto Bolli, Atul R Chugh, Domenico D'Amario, et al.
JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure|April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trialRoberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Circulation. Cardiovascular Interventions|December 17, 2017
Thirty-Day Readmission Rate and Costs After Percutaneous Coronary Intervention in the United States: A National Readmission Database AnalysisAvnish Tripathi, J Dawn Abbott, Gregg C Fonarow, et al.
Lancet (London, England)|November 18, 2011
Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trialRoberto Bolli, Atul R Chugh, Domenico D'Amario, et al.
JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure|April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trialRoberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
Pageof 4